More specifically, the use of anti-CD19/anti-BCMA CAR T cells in multiple myeloma and anti-CD19/anti-CD22 CAR T cells in ALL and diffuse large B-cell lymphoma (DLBCL) have both shown enhanced efficacy versus monotherapy [86,87,88]. This evidence concerns the gene CD19 and plasma cell myeloma.